Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-28

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy and safety of Camrelizumab plus Apatinib in the treatment of advanced non-squamous NSCLC previously treated with first-line immunotherapy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

NCT04950400

Non-small Cell Lung Cancer

UNKNOWN NA

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer

NCT04901754

Small Cell Lung Carcinoma

UNKNOWN PHASE2

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

NCT04683198

Small-cell Lung Cancer

UNKNOWN PHASE2

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

NCT04506242

NSCLC

NOT_YET_RECRUITING PHASE2

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

NCT04379739

Non Small Cell Lung Cancer

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial will evaluate the safety and efficacy of Camrelizumab plus Apatinib in participants with advanced non-squamous NSCLC previously treated with first-line immunotherapy. The primary objective of this pilot study is to determine the Camrelizumab plus Apatinib improves progression-free survival (PFS) . All the efficacy and safety are assessed by investigator : 1) response rate (ORR), 2) duration of response(DoR), 3) overall survival(OS), 4) disease control rate (DCR); the safety and quality of life assessment Explore objective is potential biomarker associated with efficacy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Non Squamous NSCLC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Camrelizumab plus Apatinib

Camrelizumab, 200mg, q3w, iv and Apatinib, 250mg, qd, po

Group Type EXPERIMENTAL

Camrelizumab

Intervention Type DRUG

A human anti-PD-1 monoclonal antibody

Apatinib

Intervention Type DRUG

A tyrosine kinase inhibitor selectively targeting VEGFR-2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Camrelizumab

A human anti-PD-1 monoclonal antibody

Intervention Type DRUG

Apatinib

A tyrosine kinase inhibitor selectively targeting VEGFR-2

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SHR-1210 Apatinibmesylate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provision of signed (infomed consent form, ICF).
2. The best response of first-line immunotherapy was SD or above, and PFS was at least 3 months.
3. Male and female aged ≥18 years and ≤75 years.
4. Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent or progressive disease following multimodal therapy.
5. Patients who are unwilling to receive chemotherapy after disease recurrence or progression during/after first-line treatment including PD-(L)1 combined with chemotherapy, and PD-(L)1 monotherapy for advanced or metastatic disease.
6. Measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria.
7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
8. Subjects are eligible if CNS metastases are asymptomatic or treated.
9. Life expectancy ≥12 weeks.
10. Fertile female must agree to use adequate contraception within 24 weeks from the beginning of the first dose of study medication to the last dose.
11. Adequate organ and marrow function.

Exclusion Criteria

1. Prior treatment with anti-tumor virus, or prior T cell co-stimulation factors,including anti-Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody or other T cell-targeted drugs.
2. Subjects who had discontinued prior treatment due to immune-related adverse events (irAEs) or who are not suitable for PD-(L)1 treatment assessed by the investigator.
3. Subjects with histologically or cytologically-documented squamous cell NSCLC.
4. Prior treatments with anti-angiogenic agents.
5. Subjects with activated EGFR gene mutation or ALK fusion mutation.
6. Untreated or active central nervous system metastases (such as brain or meningeal metastases). Subjects are eligible if CNS metastases are asymptomatic or treated and subjects are off corticosteroids for at least 2 weeks prior to first dose of study therapy.
7. Radiotherapy for the chest and whole brain should be completed within 4 weeks before the first dose of study drug (palliative radiotherapy for bone lesions should be completed before the first dose of study drugs).
8. History of active or recent history of known or suspected autoimmune disease.
9. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, radiation pneumonitis requiring steroid therapy, or evidence of active pneumonitis with clinical symptoms.
10. History of active tuberculosis regardless of prior treatment.
11. Malignancies other than NSCLC within 5 years prior to first administration of drugs, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome, such as cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and ductal carcinoma in situ after radical resection.
12. Known mental illness, alcohol abuse, inability to quit smoking, drug or drug abuse, etc.
13. Active hepatitis B or hepatitis C; History of known HIV-positive history or known AIDS.
14. Treatment with any investigational agent within 28 days of signing ICF.
15. According to the judgment of the investigator, subjects have other factors that may cause the study to be terminated halfway, such as non-compliance with the protocol, other serious diseases (including mental illness) requiring combined treatment, severe laboratory abnormalities, and Factors such as family or society will affect the safety of subjects or the collection of data and samples.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No